¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"reciprocal activation"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • activation process
    Ȱ¼ºÈ­°úÁ¤
  • complement activation
    º¸Ã¼È°¼ºÈ­, µµ¿òüȰ¼ºÈ­
  • photochemical activation
    ±¤È­ÇÐȰ¼ºÈ­
  • sleep activation
    ¼ö¸éȰ¼ºÈ­
  • ventricular activation
    ½É½ÇȰ¼ºÈ­
  • ventricular activation time
    ½É½ÇÈïºÐ½Ã°£
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • reciprocal crossing
    ¿ª±³¹è
  • dendrodendritic reciprocal synapse
    °¡Áöµ¹±â»óÈ£¿¬Á¢
  • reciprocal difference
    ¿ªÂ÷ºÐ
  • reciprocal hybrid
    »ó¹ÝÀâÁ¾
  • reciprocal inhibition
    »ó¹Ý¾ïÁ¦, »óÈ£¾ïÁ¦
  • reciprocal innervation
    »ó¹Ý½Å°æºÐÆ÷, »óÈ£½Å°æºÐÆ÷
  • reciprocal parasitism
    »óÈ£±â»ý
  • reciprocal inhibition psychotherapy
    »óÈ£¾ïÁ¦Á¤½Å¿ä¹ý
  • reciprocal rhythm
    Àç±Í¸®µë
  • reciprocal shaker
    ¿Õº¹ÁøÅÁ±â
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Innervation, reciprocal
    »óÈ£(ßÓû»)½Å°æ(ãêÌè)Áö¹è(ò¨ÛÕ)
  • reciprocal anchorage
    »ó¹Ý°íÁ¤(ßÓÚãͳïÒ), ±³Á¤(Îìïá).
  • reciprocal articulation
    »óÈ£ °üÀý(ßÓû»Î¼ï½), »ó°ü °üÀý(ßÓμμï½).
  • reciprocal beat
    »ó¹Ý¸Æ¹Ú.
  • reciprocal conduction
    »ó¹ÝÀüµµ.
  • reciprocal crossing
    »ó¹Ý±³¹è(ßÓÚãÎßÛÕ), ¿ª±³Àâ(æ½ÎßíÚ).
  • reciprocal difference
    ¿ªÂ÷ºÐ(æ½ó¬ÝÂ).
  • reciprocal hybrid
    »ó¹ÝÀâÁ¾(ßÓÚãíÚðú).
  • reciprocal inhibition
    »ó¹Ý¾ïÁ¦(ßÓÚãåäð¤).
  • reciprocal inhibition
    »óÈ£¾ïÁ¦
  • reciprocal inhibition psychotherapy
    »óÈ£Á¦ÁöÁ¤½ÅÄ¡·á.
  • reciprocal innervation
    »ó¹Ý½Å°æÁö¹è(ßÓÚããêÌèò¨ÛÕ).
  • reciprocal innervation
    »ó¹ÝÀû½Å°æÁö¹è
  • reciprocal proportion
    ¹Ýºñ·Ê(ËÑËÓËç).
  • reciprocal retention
    »ó¹ÝÁ¤Ã¼(ßÓÚãïÎôò).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • reciprocal shaker
    ¿Õº¹ÁøÅÁ±â
  • reciprocal shaker
    ¿Õº¹ÁøÅÁ±â(èÙÜÖòè.JÐï).
  • reciprocal system
    »ó¹Ý°è(ßÓÚãͧ).
  • reciprocal translocation
  • activation
    Ȱ¼ºÈ­
  • activation
    Ȱ¼ºÈ­(üÀàõûù).
  • activation analysis
    ¹æ»çÈ­ºÐ¼®, Ȱ¼ºÈ­ºÐ¼®
  • activation analysis
    Ȱ¼ºÈ­ºÐ¼®(¡­ÝÂà°), ¹æ»çÈ­(Û¯ÞÒûù)ºÐ¼®.
  • activation detector
    Ȱ¼ºÈ­ ŽÁö±â
  • activation energy
    Ȱ¼ºÈ­¿¡³ÊÁö
  • activation gate
    °³¹æ °ü¹®(ËÒÛÁμڦ)
  • activation process
    Ȱ¼ºÈ­°úÁ¤.
  • activation, polyclonal
    ´Ù¼¼Æ÷±ºÈ°¼º, ¿©·¯¹«¸®È°¼º
  • activation, polyclonal B cell
    ´Ù¼¼Æ÷±º B¼¼Æ÷Ȱ¼º, ¿©·¯¹«¸® B¼¼Æ÷Ȱ¼º
  • c3, activation
    C3, Ȱ¼º (¡­üÀàõ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • fatty acid activation
    Áö¹æ»ê Ȱ¼ºÈ­ (ò·Û¸ß«üÀàõûù)
  • feed-forward activation
    ¾Õ¸ÔÀÓ È°¼ºÈ­ (üÀàõûù)
  • gene activation
    À¯ÀüÀÚ È°¼ºÈ­(ë¶îîí­üÀàõûù)
  • macrophage activation factor
    ´ë½Ä¼¼Æ÷Ȱ¼ºÀÎÀÚ(ÓÞãÝá¬øàüÀàõì×í­)
  • neutron activation alalysis
    Áß¼ºÀÚ ¹æ»çÈ­ºÐ¼®(ñéàõí­Û¯ÞÒûùÝÂà°)
  • upstream activation sites
    À­ÂÊ È°¼ºÈ­(üÀàõûù)ÀÚ¸®
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
RHS Ramsay Hunt syndrome; Rapp-Hodgkin syndrome; reciprocal hindlimb-scratching [syndrome]; right hand s...
rom reciprocal ohm meter
RAS   1) Reticular Activating(Activation) System
  2) Renal Artery Stenosis
VAT   1) Ventricular Activation Time
  2) Video-Assisted Thoracoscopy
ADR activation, depression, repetition [in bone remodeling]; adrenodoxin reductase; Adriamycin; adverse ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
ARI activation recovery interval
AT Activation time
Ea Energy of activation
FAP Fibroblast Activation Protein
HIPA Heparin-induced platelet activation
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • receptor activation
    ¼ö¿ëü Ȱ¼ºÈ­, ¼ö¿ë±â Ȱ¼ºÈ­
  • secondary activation
    ÀÌÂ÷Àû Ȱ¼º
  • sympathetic activation
    ±³°¨½Å°æ°è Ȱ¼º
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
activation <radiobiology> Activation occurs when a particle interacts with an atomic nucleus, shifting the nucleus into an unstable state, and causing it to become radioactive.
In fusion research, where deuterium-tritium is a common fuel mixture, the neutron released when (D + T) combine to form (4He + n) can activate the reactor structure. In this case the 4He is inert, the neutron sticks to another nucleus, and the neutron + nucleus reaction creates an actvation product. Sometimes called radioactivation.
See: activation product, activation analysis.
(09 Oct 1997)
activation analysis <radiobiology> Method for identifying and measuring chemical elements in a sample of material. Sample is first made radioactive by bombardment with neutrons, charged particles, or gamma rays.
Newly formed radioactive atoms in the sample then give off characteristic radiations (such as gamma rays) that tell what kinds of atoms are present, and how many.
(09 Oct 1997)
activation energy <chemistry> The amount of energy (expressed in joules) that is needed to convert all the molecules in one mole of a reacting substance from a ground state to the transition state.
(06 May 1997)
activation product <radiobiology> The unstable nucleus formed when activation occurs. (See activation above.)
(09 Oct 1997)
amino acid activation The first step of protein synthesis, whereby an amino acid reacts with adenosine triphosphate in the presence of aminoacyl RNA synthetase to produce an amino acid adenylate, which provides the energy necessary for the attachment of the amino acid to a specific transfer RNA molecule.
(12 Dec 1998)
macrophage activation The process of altering the morphology and functional activity of macrophages so that they become avidly phagocytic. It is initiated by lymphokines, such as the macrophage activation factor (maf) and the macrophage migration-inhibitory factor (mmif), immune complexes, c3b, and various peptides, polysaccharides, and immunologic adjuvants.
(12 Dec 1998)
gene activation The process of activation of a gene so that it is expressed at a particular time. This process is crucial in growth and development.
(05 Mar 2000)
Gibbs energy of activation The Gibbs energy that must be added to that already possessed by a molecule or molecules in order to initiate a reaction.
(05 Mar 2000)
virus activation The mechanism by which latent viruses, such as genetically transmitted tumour viruses or prophages of lysogenic bacteria, are induced to replicate and are released as infectious viruses. It may be effected by various endogenous and exogenous stimuli, including B-cell lipopolysaccharides, glucocorticoid hormones, halogenated pyrimidines, ionizing radiation, ultraviolet light, and superinfecting viruses.
(12 Dec 1998)
cis activation <molecular biology> Activation of a gene by an activator located on the same chromosome i.e. Not by a diffusible product.
(18 Nov 1997)
complement activation The sequential activation of serum components c1 through c9, initiated by an erythrocyte-antibody complex or by microbial polysaccharides and properdin, and producing an inflammatory response.
(12 Dec 1998)
platelet activation A series of progressive, overlapping events triggered by exposure of the platelets to subendothelial tissue. These events include shape change, adhesiveness, aggregation, and release reactions. When carried through to completion, these events lead to the formation of a stable haemostatic plug.
(12 Dec 1998)
neutron activation analysis Activation analysis in which the specimen is bombarded with neutrons. Identification is made by measuring the resulting radioisotopes.
(12 Dec 1998)
neutrophil activation The process in which the neutrophil is stimulated by diverse substances, resulting in degranulation and/or generation of reactive oxygen products, and culminating in the destruction of invading pathogens. The stimulatory substances, including opsonised particles, immune complexes, and chemotactic factors, bind to specific cell-surface receptors on the neutrophil.
(12 Dec 1998)
EEG activation The low voltage, fast pattern of attentive wakefulness.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á